TOKYO & MUNICH, December 18, 2025--(BUSINESS WIRE)--The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY ® (datopotamab deruxtecan) ...
EMA validates Enhertu plus pertuzumab type II variation application in EU as first-line treatment of patients with HER2 positive metastatic breast cancer: Tokyo Tuesday, January 2 ...
The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for Enhertu ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback